Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein

Viral protein X (Vpx) is a human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus accessory protein that is packaged into virions in molar amounts equivalent to Gag proteins. To delineate the processes of virus assembly that mediate Vpx packaging, we used a recombinant vaccinia virus-T7 RNA polymerase system to facilitate Gag protein expression, particle assembly, and extracellular release. HIV genes were placed under control of the bacteriophage T7 promoter and transfected into HeLa cells expressing T7 RNA polymerase. Western immunoblot analysis detected p55gag and its cleavage products p39 and p27 in purified particles derived by expression of gag and gag-pol, respectively. In trans expression of vpx with either HIV-2 gag or gag-pol gave rise to virus-like particles that contained Vpx in amounts similar to that detected in HIV-2 virus produced from productively infected T cells. Using C-terminal deletion and truncation mutants of HIV-2 Gag, we mapped the p15 coding sequence for determinants of Vpx packaging. This analysis revealed a region (residues 439 to 497) downstream of the nucleocapsid protein (NC) required for incorporation of Vpx into virions. HIV-1/HIV-2 gag chimeras were constructed to further characterize the requirements for incorporation of Vpx into virions. Chimeric HIV-1/HIV-2 Gag particles consisting of HIV-1 p17 and p24 fused in frame at the C terminus with HIV-2 p15 effectively incorporate Vpx, while chimeric HIV-2/HIV-1 Gag particles consisting of HIV-2 p17 and p27 fused in frame at the C terminus with HIV-1 p15 do not. Expression of a 68-amino-acid sequence of HIV-2 containing residues 439 to 497 fused to the coding regions of HIV-1 p17 and p24 also produced virus-like particles capable of packaging Vpx in amounts similar to that of full-length HIV-2 Gag. Sucrose gradient analysis confirmed particle association of Vpx and Gag proteins. These results demonstrate that the HIV-2 Gag precursor (p55) regulates incorporation of Vpx into virions and indicates that the packaging signal is located within residues 439 to 497.

[1]  W. Haseltine,et al.  Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles , 1994, Journal of virology.

[2]  L. Ratner,et al.  HIV-2 viral protein X association with the GAG p27 capsid protein. , 1994, Virology.

[3]  W. Paxton,et al.  Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis , 1993, Journal of virology.

[4]  L. Ratner,et al.  Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions , 1993, Journal of virology.

[5]  Z. Matsuda,et al.  Vpx of simian immunodeficiency virus is localized primarily outside the virus core in mature virions , 1993, Journal of virology.

[6]  E. Hunter,et al.  Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system. , 1993, Virology.

[7]  Z. Matsuda,et al.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Kappes,et al.  Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific components. , 1993, Virology.

[9]  I. Jones,et al.  Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation. , 1992, The Journal of general virology.

[10]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[11]  M. Tristem,et al.  Evolution of the primate lentiviruses: evidence from vpx and vpr. , 1992, The EMBO journal.

[12]  Y. Iwakura,et al.  RNA packaging signal of human immunodeficiency virus type 1. , 1992, Virology.

[13]  L. Arthur,et al.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences , 1992, Journal of virology.

[14]  J. Kappes,et al.  Human immunodeficiency virus type 2 vpx protein augments viral infectivity. , 1991, Virology.

[15]  R. Gallo,et al.  Dispensable role of the human immunodeficiency virus type 2 Vpx protein in viral replication , 1991, Journal of virology.

[16]  H. Gelderblom.  Assembly and morphology of HIV: potential effect of structure on viral function. , 1991, AIDS.

[17]  B. Brinkley,et al.  Centrophilin: a novel mitotic spindle protein involved in microtubule nucleation , 1991, The Journal of cell biology.

[18]  M. Matsuda,et al.  Human immunodeficiency virus vpr gene encodes a virion-associated protein. , 1990, AIDS research and human retroviruses.

[19]  J. Orenstein,et al.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology , 1990, Journal of virology.

[20]  M. Tristem,et al.  Origin of vpx in lentiviruses , 1990, Nature.

[21]  L. Arthur,et al.  Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA , 1990, Journal of virology.

[22]  J. Sodroski,et al.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein , 1990, Journal of virology.

[23]  R. Young,et al.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus , 1990, Journal of virology.

[24]  J. Kappes,et al.  Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate , 1990, Journal of virology.

[25]  塩田 達雄.  Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV , 1990 .

[26]  J. Sodroski,et al.  Identification of HIV-1 vpr product and function. , 1990, Journal of acquired immune deficiency syndromes.

[27]  K. Nagashima,et al.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Jacobs,et al.  Assembly and release of HIV-1 precursor Pr55 gag virus-like particles from recombinant baculovirus-infected insect cells , 1989, Cell.

[29]  A. Burny,et al.  The GAG precursor of simian immunodeficiency virus assembles into virus‐like particles. , 1989, EMBO Journal.

[30]  A. Ishimoto,et al.  Mutational analysis of the human immunodeficiency virus vpr open reading frame , 1989, Journal of virology.

[31]  J. Sodroski,et al.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions , 1989, Journal of virology.

[32]  M. Emerman,et al.  VPX mutants of HIV‐2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. , 1989, The EMBO journal.

[33]  Xiao-Fang Yu,et al.  A naturally immunogenic virion-associated protein specific for HIV-2 and SIV , 1988, Nature.

[34]  R. Gallo,et al.  Monoclonal antibodies against human immunodeficiency virus (HIV) type 2 core proteins: cross-reactivity with HIV type 1 and simian immunodeficiency virus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Hood,et al.  Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC , 1988, Journal of virology.

[36]  T. Copeland,et al.  Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne) , 1988, Journal of virology.

[37]  T. Copeland,et al.  Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2. , 1988, Science.

[38]  P. Earl,et al.  Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes , 1987, Molecular and cellular biology.

[39]  M. Emerman,et al.  Genome organization and transactivation of the human immunodeficiency virus type 2 , 1987, Nature.

[40]  L. Jagodzinski,et al.  Complete nucleotide sequences of functional clones of the AIDS virus. , 1987, AIDS research and human retroviruses.

[41]  B. Moss,et al.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Kappes,et al.  Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. , 1986, The Journal of general virology.

[43]  Amanda G. Fisher,et al.  A molecular clone of HTLV-III with biological activity , 1985, Nature.